On this week’s episode of the Seekers of Meaning TV Show and Podcast, Dr. Andrew Mulberg discusses the profound implications of genetic technology, particularly CRISPR, on healthcare and aging. He explores the ethical considerations surrounding genetic manipulation, the potential for revolutionary changes in medicine, and the intersection of science and religion. The conversation also touches on the public’s mistrust of science, the role of artificial intelligence in medicine, and the FDA’s drug approval process, emphasizing the need for careful oversight in the face of rapid advancements.

You can add the Jewish Sacred Aging TV channel to your Roku streaming subscription by visiting this page: https://channelstore.roku.com/details/600964/jewish-sacred-aging.

You can also watch this week’s show in the player below. The shows now include closed-captioning for the deaf or people with a hearing loss. Click the “CC” button on the video player to activate closed-captions.

You can listen to the audio podcast version in the player below, or subscribe to the podcast in one of the popular platforms by clicking one of the buttons below the player.

• Apple Podcasts
• YouTube
• Spotify
• Podchaser
• Amazon Music

Andrew is currently an Executive pharmaceutical leader leading strategy and operational aspects of drug and biological development for NDA and BLA submissions for pediatric and adult rare diseases, cystic fibrosis, gastroenterology and hepatology.

He is currently Senior Vice President, Regulatory Affairs, Quality Assurance and Quality Control at Neurogene Inc, a company devoted to gene therapy approaches to management of neurodegenerative and neurodevelopmental disorders in children and adults including Rett syndrome.

Formerly, he served Senior Vice President, Global Regulatory Affairs at Amicus Therapeutics from 2016-2020 and responsible for the approval of Galafold (migalastat) for the treatment of Fabry disease in adults. He has been involved in the registration planning for AT-GAA, a novel enzyme replacement therapy for Pompe disease in infants, children and adults. 

He served as Division Deputy Director of Gastroenterology and Inborn Errors Products, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA) since 2010-2016.  Before joining FDA, Andrew was Portfolio Leader in Established Products responsible for worldwide leadership of Internal Medicine products in Johnson and Johnson from 2000-2010.  Andrew is a graduate of Columbia College of Columbia University and of the Mount Sinai School of Medicine.  He completed his residency in Pediatrics at the Children’s Hospital of Philadelphia followed by a Pediatric Gastroenterology Clinical Fellowship and a Post-Doctoral Fellowship in Cellular and Molecular Physiology at New England Medical Center. 

Andrew is Adjunct Professor of Pediatrics at the University of Maryland School of Medicine and has served as Attending, Pediatric Gastroenterology and Nutrition at Cooper University Hospital in New Jersey caring for children with gastrointestinal diseases.  He is Principal Editor of Pediatric Drug Development: Concepts and Applications, published in 2011 and 2013. 

He is a member of Alpha Omega Alpha Honor Medical Society, American Gastroenterological Association and the North American Society for Pediatric Gastroenterology and Nutrition.

The post Seekers of Meaning 4/18/2025: Ethical Considerations of Genetic Engineering in Medicine with Dr. Andrew Mulberg appeared first on Jewish Sacred Aging.